fda pulling semaglutide is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Hims & Hers stock falls

Wrasidlo W, Tsigelny IF, Price DL, et al

However, weight loss should happen at a steady, healthy pace

This session will discuss the differences in GLP-1As for weight loss treatment, associated eating disorder risks with using GLP-1As, and creation of a treatment plan when using these agents in the setting of an eating disorder

Completely different mechanism, which is part of why some people consider running both (more on that in a moment)

However, when it is combined with insulin or sulfonylureas, the risk of Hypoglycemia increases, and a doctor may need to adjust the doses of existing medications to maintain safe blood glucose levels